Organism: Homo sapiens
Gene: 38723_at
Selected probe(set): 209450_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38723_at (209450_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):2.4866533
Number of Samples:5 / 6

Experimental	atopic dermatitis study 21 (lesional; whole skin)
	Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control	normal skin tissue
	Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

Relative Expression (log2-ratio):2.3656473
Number of Samples:5 / 6

Experimental	atopic dermatitis study 21 (non-lesional; whole skin)
	Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control	normal skin tissue
	Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

Relative Expression (log2-ratio):-2.3234901
Number of Samples:2 / 2

Experimental	LPS study 4 (shRNA contr.)
	MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	mock treated / transduced MONO-MAC-6 cell sample
	MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

Relative Expression (log2-ratio):-2.269577
Number of Samples:2 / 2

Experimental	LPS study 4
	MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	mock treated MONO-MAC-6 cell sample
	MONO-MAC-6 (MM6) cells mock treated.

Relative Expression (log2-ratio):-2.2089815
Number of Samples:2 / 2

Experimental	LPS study 4 (shRNA cycT1)
	MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	cycT1 depletion study 2 (shRNA)
	MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

Relative Expression (log2-ratio):2.0909615
Number of Samples:2 / 2

Experimental	T-cell activation study 1
	CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control	quiescent CD4+ T-cell sample
	Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

Relative Expression (log2-ratio):1.6457052
Number of Samples:20 / 19

Experimental	atopic dermatitis study 12 (non-lesional; adults)
	Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control	atopic dermatitis study 12 (non-lesional; children)
	Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

Relative Expression (log2-ratio):1.6392508
Number of Samples:2 / 2

Experimental	conditioned medium study 1 (HS27a)
	CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control	untreated monocyte (CD14+) sample
	Untreated CD14+ monocytes from two different donors.

Relative Expression (log2-ratio):1.5630636
Number of Samples:3 / 4

Experimental	stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
	Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control	stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
	Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

Relative Expression (log2-ratio):1.5560007
Number of Samples:2 / 3

Experimental	glioma study 16 (LN-215)
	Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.